Skip to content
Kura Oncology, Inc. logo — Our mission is to realize the promise of precision medicines...

Kura Oncology, Inc.

Our mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives.

Founded 2014 United States San Diego, United States 315 employees Total: $1.17B Biotechnology, Pharmaceutical

General Information

Company Name Kura Oncology, Inc.
Founded Year 2014
Location United States San Diego, United States
Employees 315
Industries Biotechnology, Pharmaceutical
Business Model B2B, B2B2C
Revenue Model Product Sales, One Time Purchase, Licensing
Social

BounceWatch is an independent company data service, not affiliated with Kura Oncology, Inc.. To contact Kura Oncology, Inc., visit kuraoncology.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Kura Oncology, Inc. compare?

A PDF of Kura Oncology, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Kura Oncology, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Kura Oncology, Inc.

Kura Oncology, Inc., founded in 2014 and headquartered in the United States, is a leading player in the Biotechnology and Pharmaceutical sectors. The company is committed to its mission: "Our mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives." By leveraging its extensive expertise in precision oncology, Kura Oncology is working to unravel the complexities of treatment resistance to develop cutting-edge therapies.

The company is currently commercializing KOMZIFTI™ (ziftomenib), an FDA-approved oral menin inhibitor designed for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia. Their strategy focuses on creating innovative combination regimens aimed at maximizing clinical outcomes.

In its latest financial milestone, Kura Oncology secured a $150.00M private placement investment on 01 January 2024 from prominent investors EcoR1 Capital and Suvretta Capital Management. This infusion underscores investor confidence in the company’s pioneering efforts in menin and farnesyl transferase inhibition.

Business keywords: Precision Medicine, Biopharmaceuticals, Oncology, Cancer Therapeutics, Menin Inhibition, Farnesyl Transferase Inhibition, Treatment Resistance, Relapsed Acute Myeloid Leukemia, NPM1 Mutation, Smart Combination Regimens, Compound Development, Pharmaceutical Commercialization, Cancer Biology, Oral Oncology Drugs, Targeted Cancer Therapies

Services & Products

Development of novel cancer therapeutics
Precision medicine research
Investigation of drug combinations

Target Customers

Patients with cancer Caregivers Healthcare providers Investors

Funding Rounds & Investors (12)

View All
Funding Stage Amount Investors Lead Investors Date
Private Placement VC $150.00M 2
EcoR1 Capital, Suvretta Capital Management
01 Jan 2024
Post-IPO Equity $100.00M -
01 Jun 2023
Post-IPO Equity $125.00M 1
Hercules Capital
01 Nov 2022
Post-IPO Equity $345.10M -
01 Dec 2020
Post-IPO Equity $143.90M -
01 May 2020
Post-IPO Equity $115.30M -
01 Jun 2019
Post-IPO Equity $77.10M -
01 Jun 2018
Post-IPO Equity $50.10M -
01 Aug 2017
Round Undisclosed -
01 Jan 2017
IPO Undisclosed -
01 Sep 2015

View All 12 Funding Rounds

Kura Oncology, Inc. Alternatives & Competitors

View All Alternatives
Kura Oncology, Inc. vs

Developing innovative pharmaceuticals for hematological malignancies and disorders

Series C
3 employees
Biotechnology, Health Care
Kura Oncology, Inc. vs

Targeting cancer, differently.

Post-IPO Equity
27 employees
Biotechnology, Health and Wellness
Kura Oncology, Inc. vs

Targeted Therapy Delivered

Acquired
39 employees
Biotechnology, Health and Wellness

FAQ About Kura Oncology, Inc.

Our mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives.
Kura Oncology, Inc. was founded in 2014.
Kura Oncology, Inc. is headquartered in San Diego, United States.
Kura Oncology, Inc. operates in Biotechnology and Pharmaceutical. Its work centres on Precision Medicine, Biopharmaceuticals, Oncology and Cancer Therapeutics. Its customers include Patients with cancer, Caregivers and Healthcare providers.
Kura Oncology, Inc. has a B2B and B2B2C business model. Its revenue comes from Product Sales, One Time Purchase and Licensing.
Kura Oncology, Inc. has approximately 315 employees.
Kura Oncology, Inc. has completed 12 funding rounds, raising a total of $1.17B.
Kura Oncology, Inc. offers: Development of novel cancer therapeutics, Precision medicine research, Investigation of drug combinations.
Top alternatives and competitors to Kura Oncology, Inc. include Biosight Ltd., Calithera Biosciences, Lisata Therapeutics, Inc., Arcus Biosciences, TOLREMO therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Kura Oncology, Inc. and Biosight Ltd. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Kura Oncology, Inc., https://bouncewatch.com/company/kura-oncology-inc, updated 10 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout